Korro Bio Says Effective Nov 11, Co & Novo Nordisk Amend Collaboration Agreement; Co & Novo Nordisk Pause Agreement For 12 Months; Agreed To Wind-Down Its Research And Development Activities In Connection With The License Agreement

Effective November 11, 2025, Korro Bio, Inc., or Korro, and Novo Nordisk A/S, or Novo Nordisk, entered into an amendment of that certain research collaboration and license agreement dated September 13, 2024 pursuant to which Korro granted Novo Nordisk an exclusive worldwide license under certain intellectual property rights to research, develop, manufacture, commercialize or otherwise exploit certain licensed compounds and licensed products for an initial target in the cardiometabolic field and for a second target (to be nominated by Novo Nordisk within a specified time period as set forth in the agreement). Under the amendment, Korro and Novo Nordisk agreed to pause the collaboration and license agreement for 12 months, or the hold period, effective as of the date of the amendment. During the hold period, the parties agreed that all research and development activities and corresponding obligations under the agreement will be suspended without any liability or payment obligation for either party. Korro also agreed to promptly wind-down its research and development activities in connection with the license agreement and Novo Nordisk agreed to reimburse Korro for certain wind-down costs associated with the hold period. The parties agreed to continue to be bound by all other provisions of the collaboration and license agreement, including but not limited to confidentiality, exclusivity and termination provisions. Novo Nordisk's right to replace the collaboration target with a substitution target also remains in effect during the hold period.